Mainz Biomed N.V. MYNZ
We take great care to ensure that the data presented and summarized in this overview for MAINZ BIOMED N.V. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding MYNZ
View all-
Northern Trust Corp Chicago, IL29.9KShares$9,5780.0% of portfolio
-
Vontobel Holding Ltd.25KShares$8,0000.0% of portfolio
-
Geode Capital Management, LLC Boston, MA15.2KShares$4,8600.0% of portfolio
-
Xtx Topco LTD London, X011.4KShares$3,6340.0% of portfolio
-
Greenwich Investment Management, Inc. Stamford, CT10.9KShares$3,4740.0% of portfolio
-
Wealth Quarterback LLC Toms River, NJ10KShares$3,2000.0% of portfolio
-
Citigroup Inc673Shares$2150.0% of portfolio
-
Morgan Stanley New York, NY200Shares$640.0% of portfolio
-
Bank Of America Corp Charlotte, NC100Shares$320.0% of portfolio
-
Concourse Financial Group Securities, Inc. Birmingham, AL0Shares$00.0% of portfolio
Latest Institutional Activity in MYNZ
Top Purchases
Top Sells
About MYNZ
Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments on a molecular genetic basis; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany.
Insider Transactions at MYNZ
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|